AUTUMN CLARK: Open Payments
NPI 1912911090 · SPRINGFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$499 in 25 payments from 8 companies in 2025. Trend: 2023 $942 · 2024 $845 · 2025 $499
Food & beverage: $398Education: $101
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 16 | $211 |
| Teva Pharmaceuticals USA, Inc. | 1 | $101 |
| Neurocrine BioSciences, Inc. | 2 | $68 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| Alkermes, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Products named: COBENFY, INGREZZA, Auvelity, CAPLYTA, ABILIFY ASIMTUFII, REXULTI, ARISTADA, Qelbree.
Industry payments across MO — which companies pay providers there.
